• Users Online: 356
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 43  |  Issue : 3  |  Page : 138-144

‘Gatekeeper’ mutation in patients with chronic myeloid leukemia resistant to imatinib therapy: effect on survival


Department of Haematology, Medical Research Institute, Alexandria University, Alexandria, Egypt

Correspondence Address:
Mohamed A.M El-Menoufy
Department of Hematology, Medical Research Institute, Alexandria 21561
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejh.ejh_18_18

Rights and Permissions

Background T315I is the most difficult type of point mutation that appears during treatment of chronic myeloid leukemia (CML). It represents kind of a ‘gatekeeper’ that controls access of small molecule inhibitors and confers resistance to the most known tyrosine kinase inhibitors. Aim The aim of the present study was to assess the characteristics of Egyptian patients with CML harboring T315I mutation and to evaluate its effect on the patients’ survival. Patients and methods A total of 45 patients with CML in chronic phase resistant to imatinib mesylate (IM) treatment were enrolled in this study. Allele-specific oligonucleotide-PCR was used to detect T315I BCR-ABL gene mutation in all patients at the time of IM resistance. Results T315I mutation was present in 11 (24.4%) patients. The level of resistance was heterogeneous. Responses were observed in two resistant T315+ patients with IM dose escalation and three patients who were shifted to second-generation tyrosine kinase inhibitor. There was no significant difference in patient characteristics and overall survival between T315I+ and T315I resistant patients. Overall survival is significantly associated with the duration of response and the phase of the disease at the time of resistance. Conclusion Evaluation of T315I mutation is recommended in all patients with CML, even in the early phase of the disease, which may be subsequently associated with resistance or progression of their disease in the future and requires the need for an alternative therapeutic option(s).


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed27    
    Printed0    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal